Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
2
40%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

recruiting480%
active_not_recruiting120%

Recent Activity

5 active trials
Showing 5 of 5
active_not_recruitingphase_2

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

NCT05767359
recruitingphase_1

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

NCT06623630
recruitingphase_2

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT06940297
recruitingphase_1

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

NCT07093554
recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

NCT06855121

Clinical Trials (5)

Showing 5 of 5 trials
NCT05767359Phase 2

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Active Not Recruiting
NCT06623630Phase 1

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Recruiting
NCT06940297Phase 2

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT07093554Phase 1

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5